A Study of Continued Use of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting

The purpose of this study is to find out how long a participant keeps taking guselkumab or continues with their treatment plan without stopping (treatment persistence) in participants with moderate to severe Crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are inflammatory bowel diseases, a group of inflammatory conditions of the colon and small intestine.

NCT Number	NCT07746765
Lead Sponsor	Janssen Sciences Ireland UC
Conditions	Crohn Disease, Colitis, Ulcerative
Enrollment	35 participants
Start Date	2026-08-03
Primary Completion	2029-08-03 (estimated)
Study Completion	2029-08-03 (estimated)
Updated on ClinicalTrials.gov	2026-08-05